Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
PROGRAM DESCRIPTION Nonalcoholic fatty liver disease (NAFLD) is a potentially progressive spectrum of liver disorders that includes among its more severe forms nonalcoholic steatohepatitis (NASH).1 Closely associated with rising rates ...
Nonalcoholic fatty liver disease (NAFLD) is a potentially progressive spectrum of liver disorders that includes among its more severe forms nonalcoholic steatohepatitis (NASH).1 Closely associated with rising rates of obesity and metabolic syndrome, the prevalence of NAFLD and NASH continues to trend upward, suggesting that over the next decade, patients, clinicians, and health care systems will face an exponential increase in burdens associated with this underrecognized epidemic.2-4 In addition to having a strong foundation in current best practices for NAFLD/NASH management, clinicians involved in the care of patients with or at risk for NASH must be prepared to appropriately integrate newer noninvasive diagnostic modalities into patient workups and have a good understanding of the mechanisms of action, latest efficacy and safety data, and potential prescribing considerations for the numerous NASH therapies currently in late-stage development.5,6 During this Evidence-Based Best PracticesTM program, expert faculty will use animated illustrations to highlight clinically relevant pathways in the complex pathophysiologic mechanisms of NAFLD and NASH; discuss current recommendations on the use of liver biopsy and complementary, noninvasive modalities for NASH diagnosis and staging; interpret the latest evidence for emerging NASH therapies; and, share their preferred risk-stratification strategies to predict prognoses, shape management decisions, and monitor disease progression.4-7References1. Haas JT, et al. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181-205.2. Hassan K, et al. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World J Gastroenterol. 2014;20(34):12082-12101.3. Estes C, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2017 Aug 12 [Epub ahead of print].4. Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5):774.5. Renelus B, Foster T. Noninvasive evaluation of nonalcoholic fatty liver disease. Clin Liver Dis. 2016;7(3):45-47.6. Banini BA, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2017;33(3):134-141.7. Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2017;37(suppl 1):85-89.
After completing this activity, the participant should be better able to:Use current epidemiologic and demographic data to enhance NASH identificationDescribe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkersSelectively employ liver biopsy and complementary noninvasive modalities for NAFLD/NASH diagnosis, staging, and monitoringDiscuss the emerging NASH therapies, including the combined use of agents with complementary mechanisms of actionMonitor patients over time for NASH progression and hepatocellular carcinoma, including proactive identification of appropriate patients for enrollment in clinical trials
I'm interested in this
Share with others
Write the first review
Share with others